


Figure 9

Number of Dose Increases (Upper) or Decreases (Lower) of Phenytoin in 912-US by Treatment
(0=placebo; 1=zonisamide)




APPEARS THIS WAY
ON ORIGINAL

APPEARS THIS WAY
ON ORIGINAL

Figure 10

Number of Dose Increases (Upper) or Decreases (Lower) of Valproic Acid in 912-US by Treatment (0=placebo; 1=zonisamide)




APPEARS THIS WAY
ON ORIGINAL

APPEARS THIS WAY
ON ORIGINAL

Figure 11

Number of Dose Increases (Upper) or Decreases (Lower) of Phenobarbital in 912-US by Treatment (0=placebo; 1=zonisamide)



APPEARS THIS WAY
ON ORIGINAL

APPEARS THIS WAY
ON ORIGINAL

Figure 12

Number of Dose Increases (Upper) or Decreases (Lower) of Priridone in 912-US by Treatment (0=placebo; 1=zonisamide)





Figure 13

Plasma Level of Carbamazepine vs. Relative Study Day for Placebo Subjects in the Controlled Portion of 912-US




APPEARS THIS WAY
ON ORIGINAL

Figure 14

Plasma Level of Carbamazepine vs. Relative Study Day for Zonisamide Subjects in the Controlled Portion of 912-US


912-US-P1-Plasma-Conc\CTLTW=ZONISAMIDE DRUG=CARBAMAZEPINE P



APPEARS THIS WAY
ON ORIGINAL

Figure 15


Plasma Level of Phenytoin vs. Relative Study Day for Placebo Subjects in the Controlled Portion of 912-US



APPEARS THIS WAY
ON ORIGINAL

Figure 16

Plasma Level of Phenytoin vs. Relative Study Day for Zonisamide Subjects in the Controlled Portion of 912-US




APPEARS THIS WAY
ON ORIGINAL

APPEARS THIS WAY
ON ORIGINAL

Figure 17

Plasma Level of Valproic Acid vs. Relative Study Day for Placebo Subjects in the Controlled Portion of 912-US




APPEARS THIS WAY
ON ORIGINAL

APPEARS THIS WAY
ON ORIGINAL

Figure 18

Plasma Level of Valproic Acid vs. Relative Study Day for Zonisamide Subjects in the Controlled Portion of 912-US

912-US-PT-Plasma-Con-CTLTM=ZONISAMIDE DRUG=VALPROIC ACID P




APPEARS THIS WAY
ON ORIGINAL

APPEARS THIS WAY
ON ORIGINAL

Figure 19


Plasma Level of Phenobarbital vs. Relative Study Day for Placebo Subjects in the Controlled Portion of 912-US



APPEARS THIS WAY
ON ORIGINAL

Figure 20


Plasma Level of Phenobarbital vs. Relative Study Day for Zonisamide Subjects in the Controlled Portion of 912-US



APPEARS THIS WAY
ON ORIGINAL

Figure 21


Plasma Level of Primidone vs. Relative Study Day for Placebo Subjects in the Controlled Portion of 912-US



APPEARS THIS WAY
ON ORIGINAL

Figure 22


Plasma Level of Primidone vs. Relative Study Day for Zonisamide Subjects in the Controlled Portion of 912-US



APPEARS THIS WAY
ON ORIGINAL

Figure 23


Plasma Level of Zonisamide vs. Relative Study Day for Placebo Subjects in the Controlled Portion of 912-US



APPEARS THIS WAY
ON ORIGINAL

Figure 24

Plasma Level of Zonisamide vs. Relative Study Day for Zonisamide Subjects in the Controlled Portion of 912-US



APPEARS THIS WAY
ON ORIGINAL

Table 27

Zonisamide Levels in Placebo Subjects in the Controlled Phase of Study US-912


Zonisamide Levels in Placebo Subjects in the Controlled Phase of Study US-912							
PATID 912-US	PATNO 912-US	CNTL_TMT	PHASE_C	DRUG	ISSL EVEL	DATE1	RELDAY
1755111	11	PLACEBO	Controlled	ZONISAMIDE	2.1	4/9/84	55
1755113	13	PLACEBO	Controlled	ZONISAMIDE	2.86	3/21/84	29
1755113	13	PLACEBO	Controlled	ZONISAMIDE	0.524	4/18/84	57
1755115	15	PLACEBO	Controlled	ZONISAMIDE	3.5	3/21/84	1
1755115	15	PLACEBO	Controlled	ZONISAMIDE	1.84	4/9/84	20
1755117	17	PLACEBO	Controlled	ZONISAMIDE	0.488	5/2/84	1
1755121	21	PLACEBO	Controlled	ZONISAMIDE	8.8	7/30/84	1
175514	4	PLACEBO	Controlled	ZONISAMIDE	0.678	3/28/84	85
175515	5	PLACEBO	Controlled	ZONISAMIDE	0.342	4/2/84	78
175519	9	PLACEBO	Controlled	ZONISAMIDE	2.02	4/4/84	57
175519	9	PLACEBO	Controlled	ZONISAMIDE	1.18	5/2/84	85

APPEARS THIS WAY
ON ORIGINAL

APPEARS THIS WAY
ON ORIGINAL

Figure 25

Subjects with Dose Increases (Upper) or Decreases (Lower) of Concomitant AEDs in 912-EUR by Treatment (0=placebo; 1=zonisamide)



APPEARS THIS WAY
ON ORIGINAL

APPEARS THIS WAY
ON ORIGINAL

BEST POSSIBLE COPY

Figure 26

Number of Dose Increases (Upper) or Decreases (Lower) of Concomitant AEDs in 912-EUR by Treatment (0=placebo; 1=zonisamide)





Figure 27

Number of Dose Increases (Upper) or Decreases (Lower) of Carbamazepine in 912-EUR by Treatment (0=placebo; 1=zonisamide)




BEST POSSIBLE COPY

APPEAR THIS WAY
ON ORIGINAL

APPEAR THIS WAY
ON ORIGINAL

Figure 28

Number of Dose Increases (Upper) or Decreases (Lower) of Phenytoin in 912-EUR by Treatment (0=placebo; 1=zonisamide)



APPEARS THIS WAY
ON ORIGINAL

APPEARS THIS WAY
ON ORIGINAL

BEST POSSIBLE COPY

Figure 29

Number of Dose Increases (Upper) or Decreases (Lower) of Valproic Acid in 912-EUR by Treatment (0=placebo; 1=zonisamide)

[illegible]

APPEARANCE, PLAY
OF ORIGINAL

APPEARS THIS WAY
ON ORIGINAL

Figure 30

Number of Dose Increases (Upper) or Decreases (Lower) of Phenobarbital in 912-EUR by Treatment (0=placebo; 1=zonisamide)




Figure 31

Number of Dose Increases (Upper) or Decreases (Lower) of Primidone in 912-EUR by Treatment (0=placebo; 1=zonisamide)

R-20-0007789-001-00000-00000

Form 31 (EUR)

0.75
0.5
0.25

PLACEBO ZONISAMIDE

CHT1, TWT

CHT1, TWT

Count	PLACEBO	ZONISAMIDE	
Cell 0			
0	69	73	121
1	10.00	97.30	
2	1	7	3
3	2.00	3.70	
	70	70	120

Sum

Sum	0	1	2	3
Sum	1	0.021944	0.0023	
Sum	122	10.000000	0.000000	
C Total	122	10.120000		
Total Count	120			

Chi-Square

Chi-Square	DF	P-Value
Chi-Square	0.000	0.999
P-Value	0.000	0.999

Chi-Square Test

Chi-Square	DF	P-Value
Chi-Square	0.000	0.999
P-Value	0.000	0.999

Sum

Sum	0	1	2	3
Sum	1	0.021944	0.0023	
Sum	122	10.000000	0.000000	
C Total	122	10.120000		
Total Count	120			

Chi-Square

Chi-Square	DF	P-Value
Chi-Square	0.000	0.999
P-Value	0.000	0.999

Chi-Square Test

Chi-Square	DF	P-Value
Chi-Square	0.000	0.999
P-Value	0.000	0.999


APPEARS THIS WAY
ON ORIGINAL

APPEARS THIS WAY
ON ORIGINAL

BEST POSSIBLE COPY

Figure 32


Plasma Level of Cabamazepine vs. Relative Study Day for Placebo Subjects in the Controlled Portion of 912-EUR



APPEARS THIS WAY
ON ORIGINAL

Figure 33

Plasma Level of Cabamazepine vs. Relative Study Day for Zonisamide
Subjects in the Controlled Portion of 912-EUR




APPEARS THIS WAY
ON ORIGINAL

Figure 34

Plasma Level of Phenytoin vs. Relative Study Day for Placebo Subjects in the Controlled Portion of 912-EUR

912-EUR-PT-Plasma-Control(CNTLTM=PLACEBO DRUG=PHENYTOIN)




APPEARS THIS WAY
ON ORIGINAL

Figure 35

Plasma Level of Phenytoin vs. Relative Study Day for Zonisamide Subjects in the Controlled Portion of 912-EUR

912-EUR-PT-Plasma-Control(CNTL)W=ZONISAMIDE DRUG=PHENYTOIN




APPEARS THIS WAY
ON ORIGINAL

Figure 36

Plasma Level of Valproic Acid vs. Relative Study Day for Placebo Subjects in the Controlled Portion of 912-EUR


912-EUR-PT-Plasma-Control(CNTL)TW=PLACEBO DRUG=VALPROIC ACID)



APPEARS THIS WAY
ON ORIGINAL

Figure 37


Plasma Level of Valproic Acid vs. Relative Study Day for Zonisamide Subjects in the Controlled Portion of 912-EUR



APPEARS THIS WAY
ON ORIGINAL

Figure 38


Plasma Level of Phenobarbital vs. Relative Study Day for Placebo Subjects in the Controlled Portion of 912-EUR



APPEARS THIS WAY
ON ORIGINAL

Figure 39

Plasma Level of Phenobarbital vs. Relative Study Day for Zonisamide Subjects in the Controlled Portion of 912-EUR




APPEARS THIS WAY
ON ORIGINAL

Figure 40

Plasma Level of Primidone vs. Relative Study Day for Placebo Subjects in the Controlled Portion of 912-EUR


912-EUR-PT-Plasma-Control(CNTL)F=PLACEBO DRUG=PRIMIDONE



APPEARS THIS WAY
ON ORIGINAL

Figure 41


Plasma Level of Primidone vs. Relative Study Day for Zonisamide Subjects
in the Controlled Portion of 912-EUR



APPEARS THIS WAY
ON ORIGINAL

Figure 42

Plasma Level of Zonisamide vs. Relative Study Day for Placebo Subjects in the Controlled Portion of 912-EUR



APPEARS THIS WAY
ON ORIGINAL

Figure 43

Plasma Level of Zonisamide vs. Relative Study Day for Zonisamide Subjects in the Controlled Portion of 912-EUR

912-EUR-PF-Plasma-Control(CNTLTM=ZONISAMIDE DRUG=ZONISAMIDE)





Figure 44


Zonisamide Doses in 912-EUR



APPEARS THIS WAY
ON ORIGINAL

Figure 45


Zonisamide Doses During the Controlled Portion of 912-EUR



APPEARS THIS WAY
ON ORIGINAL

Figure 46


Zonisamide Plasma Levels in 912-EUR



APPEARS THIS WAY
ON ORIGINAL

Figure 47


Zonisamide Plasma Levels During the Controlled Portion of 912-EUR



APPEARS THIS WAY
ON ORIGINAL

Figure 48

Subjects with Dose Increases (Upper) or Decreases (Lower) of Concomitant AEDs in 922-US by Treatment (0=placebo; 1=zonisamide)




APPEARS THIS WAY
ON ORIGINAL

BEST POSSIBLE COPY

Figure 49

Number of Dose Increases (Upper) or Decreases (Lower) of Carbamazepine in 922-US by Treatment (0=placebo; 1=zonisamide)




APPEARS THIS WAY
ON ORIGINAL

BEST POSSIBLE COPY

Figure 50


Number of Dose Increases (Upper) or Decreases (Lower) of Phenytoin in 922-US by Treatment (0=placebo; 1=zonisamide)



APPEARS THIS WAY
ON ORIGINAL

BEST POSSIBLE COPY

Number of Dose Increases (Upper) or Decreases (Lower) of Valproic Acid in 922-US by Treatment (0=placebo; 1=zonisamide)




APPEARS THIS WAY
ON ORIGINAL

BEST POSSIBLE COPY

Figure 52

Number of Dose Increases (Upper) or Decreases (Lower) of Phenobarbital in 922-US by Treatment (0=placebo; 1=zonisamide)




APPEARS THIS WAY
ON ORIGINAL

BEST POSSIBLE COPY

Figure 53

Number of Dose Increases (Upper) or Decreases (Lower) of Other AEDs in 922-US by Treatment (0=placebo; 1=zonisamide)



APPEARS THIS WAY
ON ORIGINAL

BEST POSSIBLE COPY

Figure 54

Plasma Level of Carbamazepine vs. Relative Study Day for Placebo Subjects in the Controlled Portion of 922-US

922-US-PT-Plasma-Conc(CNTL.TMF=PLACEBO DRUG=CARBAMAZEPINE)





Figure 55

Plasma Level of Carbamazepine vs. Relative Study Day for Zonisamide Subjects in the Controlled Portion of 922-US

922-US-PT-Plasma-ConCtrl(CNTL)TW=ZONISAMIDE DRUG=CARBAMAZEPINE



APPEARS THIS WAY
ON ORIGINAL